Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

risedronate

risedronate
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Atelvia DELAYED RELEASE TABLET, ORAL 35 mg      
Actonel TABLET, ORAL 5 mg, 35 mg, 75 mg, 150 mg      
Actonel TABLET, ORAL 30 mg    


Comments:

ORDER FORMULATION

THERAPEUTIC INTERCHANGE

NOTES

risedronate (Actonel)

  • 30 mg tablet oral

alendronate (Fosamax)

  • 35 mg tablet oral

Daily for Paget's Disease


Actonel medication guide

Atelvia medication guide


Automatic discontinuation of oral bisphosphonates for inpatients due to safety risk involving patient required to remain in upright position for at least 30 minutes, to take with a full glass of water, to hold food, other liquids and drugs for at least 30 minutes after dose, and several other issues. Exception: alendronate 35 mg stocked for rare cases of Paget's Disease.


Reviewed: May 22, 2007 (Actonel 75 mg tablets) and June 24, 2008 (Actonel 150 mg tablets) and January 27, 2009 (Oral Bisphosphonates) and April 26, 2011 (Atelvia)


Last updated: Dec. 18, 2017







This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.